Arcus Biosciences Inc (RCUS)
Debt-to-capital ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 485,000 | 462,000 | 657,000 | 842,000 | 502,000 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $485,000K)
= 0.00
Arcus Biosciences Inc has consistently maintained a debt-to-capital ratio of 0.00 from December 31, 2020, to December 31, 2024. This indicates that the company has not used debt financing to fund its operations or growth during this period. A debt-to-capital ratio of zero, in this case, implies that the company's capital structure is primarily equity-financed, which can be seen as a positive sign in terms of financial stability and risk management.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-capital ratio
Arcus Biosciences Inc
RCUS
0.00
Abbott Laboratories
ABT
0.26
AbbVie Inc
ABBV
0.00
ACADIA Pharmaceuticals Inc
ACAD
0.00
Alkermes Plc
ALKS
0.00
Amphastar P
AMPH
0.46
ANI Pharmaceuticals Inc
ANIP
0.40
Biomarin Pharmaceutical Inc
BMRN
0.10
Bristol-Myers Squibb Company
BMY
0.74
Catalyst Pharmaceuticals Inc
CPRX
0.00
Collegium Pharmaceutical Inc
COLL
0.71